EuroAPI is counting on 2024 to be its “year of transition” as the small molecule producer plans to discontinue API assets, potentially make layoffs and “mothball” or divest sites. Its restructuring project, dubbed FOCUS-27, will be driven by its newly appointed CEO, Ludwig de Mot.
Nonetheless, the stock $EAPI.PA of EuroAPI — a Sanofi API spinoff — plummeted by as much as 45% on Thursday after the company detailed its plans on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.